145 related articles for article (PubMed ID: 12097198)
1. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.
van Tol KM; Jager PL; Piers DA; Pruim J; de Vries EG; Dullaart RP; Links TP
Thyroid; 2002 May; 12(5):381-7. PubMed ID: 12097198
[TBL] [Abstract][Full Text] [Related]
2. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
3. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
Petrich T; Börner AR; Otto D; Hofmann M; Knapp WH
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):641-7. PubMed ID: 11976802
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.
Chin BB; Patel P; Cohade C; Ewertz M; Wahl R; Ladenson P
J Clin Endocrinol Metab; 2004 Jan; 89(1):91-5. PubMed ID: 14715833
[TBL] [Abstract][Full Text] [Related]
5. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
[TBL] [Abstract][Full Text] [Related]
7. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
8. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
[TBL] [Abstract][Full Text] [Related]
11. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Leboulleux S; Schroeder PR; Busaidy NL; Auperin A; Corone C; Jacene HA; Ewertz ME; Bournaud C; Wahl RL; Sherman SI; Ladenson PW; Schlumberger M
J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
[TBL] [Abstract][Full Text] [Related]
13. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.
Saab G; Driedger AA; Pavlosky W; McDonald T; Wong CY; Yoo J; Urbain JL
Thyroid; 2006 Mar; 16(3):267-72. PubMed ID: 16571089
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
15. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
16. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM
J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836
[TBL] [Abstract][Full Text] [Related]
17. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis.
Ma C; Xie J; Lou Y; Gao Y; Zuo S; Wang X
Eur J Endocrinol; 2010 Aug; 163(2):177-83. PubMed ID: 20484385
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports.
Huang TS; Chieng PU; Chang CC; Yen RF
J Endocrinol Invest; 1998 Jun; 21(6):392-8. PubMed ID: 9699132
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
20. TSH suppression aggravates arterial inflammation - an
Boswijk E; Sanders KJC; Broeders EPM; de Ligt M; Vijgen GHEJ; Havekes B; Mingels AMA; Wierts R; van Marken Lichtenbelt WD; Schrauwen P; Mottaghy FM; Wildberger JE; Bucerius J
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1428-1438. PubMed ID: 30859432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
